1. Home
  2. TVRD vs JILL Comparison

TVRD vs JILL Comparison

Compare TVRD & JILL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • JILL
  • Stock Information
  • Founded
  • TVRD 2017
  • JILL 1959
  • Country
  • TVRD United States
  • JILL United States
  • Employees
  • TVRD N/A
  • JILL N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • JILL Clothing/Shoe/Accessory Stores
  • Sector
  • TVRD Health Care
  • JILL Consumer Discretionary
  • Exchange
  • TVRD Nasdaq
  • JILL Nasdaq
  • Market Cap
  • TVRD 246.5M
  • JILL 233.1M
  • IPO Year
  • TVRD N/A
  • JILL 2017
  • Fundamental
  • Price
  • TVRD $28.98
  • JILL $16.00
  • Analyst Decision
  • TVRD Strong Buy
  • JILL Strong Buy
  • Analyst Count
  • TVRD 2
  • JILL 5
  • Target Price
  • TVRD $52.00
  • JILL $33.40
  • AVG Volume (30 Days)
  • TVRD 48.4K
  • JILL 82.0K
  • Earning Date
  • TVRD 05-13-2025
  • JILL 06-11-2025
  • Dividend Yield
  • TVRD N/A
  • JILL 1.38%
  • EPS Growth
  • TVRD N/A
  • JILL 3.98
  • EPS
  • TVRD N/A
  • JILL 2.61
  • Revenue
  • TVRD N/A
  • JILL $610,857,000.00
  • Revenue This Year
  • TVRD N/A
  • JILL $3.91
  • Revenue Next Year
  • TVRD N/A
  • JILL $3.30
  • P/E Ratio
  • TVRD N/A
  • JILL $6.13
  • Revenue Growth
  • TVRD N/A
  • JILL 0.46
  • 52 Week Low
  • TVRD $8.13
  • JILL $14.37
  • 52 Week High
  • TVRD $34.31
  • JILL $40.61
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • JILL 45.17
  • Support Level
  • TVRD N/A
  • JILL $15.86
  • Resistance Level
  • TVRD N/A
  • JILL $16.28
  • Average True Range (ATR)
  • TVRD 0.00
  • JILL 0.59
  • MACD
  • TVRD 0.00
  • JILL -0.03
  • Stochastic Oscillator
  • TVRD 0.00
  • JILL 7.78

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About JILL J. Jill Inc.

J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.

Share on Social Networks: